SecBot SecBot
SECBOTREPLAY Home › Report › FULC

FULC · Fulcrum Therapeutics reported Q1 2026 net loss of $18.9M ($0.25 per…

Fulcrum Therapeutics, Inc. · PRESS-RELEASE filed Apr 27, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Apr 27, 2026 at 07:00 ET

Fulcrum Therapeutics reported Q1 2026 net loss of $18.9M ($0.25 per share), slightly narrower than the consensus estimate of a $0.30 loss. The company highlighted positive clinical data for pociredir in sickle cell disease, plans to initiate a registration-enabling trial in H2 2026, and ended the quarter with $333.3M in cash, providing runway into 2029. CFO Alan Musso announced retirement later this year.

  • Q1 2026 net loss of $18.9M ($0.25 per share) vs consensus estimate of $0.30 loss per share
  • Cash, cash equivalents and marketable securities of $333.3M as of March 31, 2026, down from $352.3M at year-end 2025
  • Positive clinical data from Phase 1b PIONEER trial of pociredir in sickle cell disease presented in Q1 2026
  • Plans to initiate a potential registration-enabling trial for pociredir in H2 2026 pending FDA feedback

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access